Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | AM-580 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | silmitasertib | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.7 |
mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |
mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | Erlotinib | FIMM | pan-cancer | AAC | -0.068 | 0.7 |
mRNA | Topotecan | FIMM | pan-cancer | AAC | -0.042 | 0.7 |
mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.067 | 0.7 |
mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.014 | 0.7 |